Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Cancer Immunology, Immunotherapy

Volumn 60, Issue 2, 2011, Pages 249-260

  Lesterhuis, W Joost ^a   Schreibelt, Gerty ^b   Scharenborg, Nicole M ^b   Brouwer, H Mary Lène H ^b   Gerritsen, Marie Jeanne P ^a   Croockewit, Sandra ^a   Coulie, Pierre G ^c   Torensma, Ruurd ^b   Adema, Gosse J ^b   Figdor, Carl G ^b   De Vries, I Jolanda M ^b   Punt, Cornelis J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DE DUVE INSTITUTE   (Belgium)

Author keywords

Altered peptide ligands; Dendritic cells; Immunotherapy; Melanoma; Monitoring

Indexed keywords

DENDRITIC CELL VACCINE; KEYHOLE LIMPET HEMOCYANIN; LYSYLTHREONYLTRYPTOPHYLGLYCYLGLUTAMINYLTYROSYLTRYPTOPHYLALANYLVALINE; LYSYLTHREONYLTRYPTOPHYLGLYCYLGLUTAMINYLTYROSYLTRYPTOPHYLGLUTAMINYLVALINE; PEPTIDE; TYROSYLLEUCYLGLUTAMYLPROPYLGLYCYLPROPYLVALYLTHREONYLALANINE; TYROSYLLEUCYLGLUTAMYLPROPYLGLYCYLPROPYLVALYLTHREONYLVALINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; INJECTION SITE REACTION; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SKIN BIOPSY; T LYMPHOCYTE; WILD TYPE;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; GP100 MELANOMA ANTIGEN; HUMANS; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79151468702     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0942-x     Document Type: Article

References (28)

1. J Banchereau RM Steinman 1998 Dendritic cells and the control of immunity Nature 392 245 252 1:CAS:528:DyaK1cXitFWrsr8%3D 10.1038/32588 9521319
2. WJ Lesterhuis EHJG Aarntzen IJM Vries DH Schuurhuis CG Figdor GJ Adema CJA Punt 2008 Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66 118 134 1:STN:280:DC%2BD1c3islCqsA%3D%3D 10.1016/j.critrevonc.2007.12.007 18262431
3. J Banchereau AK Palucka M Dhodapkar S Burkeholder N Taquet A Rolland S Taquet S Coquery KM Wittkowski N Bhardwaj L Pineiro R Steinman J Fay 2001 Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine Cancer Res 61 6451 6458 1:CAS:528:DC%2BD3MXmsF2jsbw%3D 11522640
4. IJM de Vries WJ Lesterhuis NM Scharenborg LPH Engelen DJ Ruiter MJP Gerritsen S Croockewit CM Britten R Torensma GJ Adema CG Figdor CJA Punt 2003 Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients Clin Cancer Res 9 5091 5100 14613986
5. IJM de Vries DJEB Krooshoop NM Scharenborg WJ Lesterhuis JHS Diepstra GNP van Muijen SP Strijk TJ Ruers OC Boerman WJG Oyen GJ Adema CJA Punt CG Figdor 2003 Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state Cancer Res 63 12 17 12517769
6. IJM de Vries MR Bernsen WJ Lesterhuis NM Scharenborg SP Strijk MJP Gerritsen DJ Ruiter CG Figdor CJA Punt GJ Adema 2005 Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome J Clin Oncol 23 5779 5787 10.1200/JCO.2005.06.478 16110035
7. IJM de Vries WJ Lesterhuis JO Barentsz P Verdijk JH van Krieken OC Boerman WJG Oyen JJ Bonenkamp JB Boezeman GJ Adema JWM Bulte TWJ Scheenen CJA Punt A Heerschap CG Figdor 2005 Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy Nat Biotechnol 23 1407 1413 10.1038/nbt1154 16258544
8. WJ Lesterhuis IJM de Vries DH Schuurhuis ACI Boullart JFM Jacobs AJ de Boer NM Scharenborg HMH Brouwer MWMM van de Rakt CG Figdor TJ Ruers GJ Adema CJA Punt 2006 Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests Ann Oncol 17 974 980 1:STN:280:DC%2BD283nslentA%3D%3D 10.1093/annonc/mdl072 16600979
9. B Schuler-Thurner ES Schultz TG Berger G Weinlich S Ebner P Woerl A Bender B Feuerstein PO Fritsch N Romani G Schuler 2002 Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells J Exp Med 195 1279 1288 1:CAS:528:DC%2BD38XjvFegt7Y%3D 10.1084/jem.20012100 12021308
10. CG Figdor IJM de Vries WJ Lesterhuis CJM Melief 2004 Dendritic cell immunotherapy: mapping the way Nat Med 10 475 480 1:CAS:528:DC%2BD2cXjsF2jtLs%3D 10.1038/nm1039 15122249
11. BJ Van den Eynde P van der Bruggen 1997 T cell defined tumor antigens Curr Opin Immunol 9 684 693 10.1016/S0952-7915(97)80050-7 9368778
12. ABH Bakker SH van der Burg RJF Huijbens JW Drijfhout CJM Melief GJ Adema CG Figdor 1997 Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope Int J Cancer 70 302 309 1:CAS:528:DyaK2sXhs1Onu7k%3D 10.1002/(SICI)1097-0215(19970127)70: 3<302::AID-IJC10>3.0.CO;2-H 9033632
13. MR Parkhurst ML Salgaller S Southwood PF Robbins A Sette SA Rosenberg Y Kawakami 1996 Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A 0201-binding residues J Immunol 157 2539 2548 1:CAS:528:DyaK28Xls1aitr4%3D 8805655
14. CM Balch AC Buzaid SJ Soong MB Atkins N Cascinelli DG Coit ID Fleming JE Gershenwald A Houghton JM Kirkwood KM McMasters MF Mihm DL Morton DS Reintgen MI Ross A Sober JA Thompson JF Thompson 2001 Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 3635 3648 1:STN:280:DC%2BD3MvlvV2ktQ%3D%3D 11504745
15. U Keilholz SH Goey CJ Punt TM Proebstle R Salzmann C Scheibenbogen D Schadendorf D Liénard A Enk R Dummer B Hantich AM Geueke AM Eggermont 1997 Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group J Clin Oncol 15 2579 2588 1:CAS:528:DyaK2sXkslyms74%3D 9215828
16. Y Tsuchida P Therasse 2001 Response evaluation criteria in solid tumors (RECIST): new guidelines Med Pediatr Oncol 37 1 3 1:STN:280: DC%2BD3MvhsFCjug%3D%3D 10.1002/mpo.1154 11466715
17. IJM de Vries AAO Eggert NM Scharenborg JLM Vissers WJ Lesterhuis OC Boerman CJA Punt GJ Adema CG Figdor 2002 Phenotypical and functional characterization of clinical grade dendritic cells J Immunother 25 429 438 10.1097/00002371-200209000-00007 12218781
18. B Thurner C Roder D Dieckmann H Heuer M Kruse A Glaser P Keikavoussi E Kampgen A Bender G Schuler 1999 Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application J Immunol Methods 223 1 15 1:CAS:528:DyaK1MXksFKqtw%3D%3D 10.1016/S0022-1759(98) 00208-7 10037230
19. ABH Bakker MWJ Schreurs G Tafazzul AJ de Boer Y Kawakami GJ Adema CG Figdor 1995 Identification of a novel peptide derived from the melanocyte-specific Gp100 antigen as the dominant epitope recognized by an Hla-A2.1-restricted antimelanoma Ctl line Int J Cancer 62 97 102 1:CAS:528:DyaK2MXnt1Cjtbg%3D 10.1002/ijc.2910620118 7541395
20. AL Cox J Skipper Y Chen RA Henderson TL Darrow J Shabanowitz VH Engelhard DF Hunt CL Slingluff 1994 Identification of a peptide recognized by 5 melanoma-specific human cytotoxic T-cell lines Science 264 716 719 1:CAS:528:DyaK2cXltVKisbc%3D 10.1126/science.7513441 7513441
21. T Wolfel J Schneider KHM Zumbuschenfelde HG Rammensee O Rotzschke K Falk 1994 Isolation of naturally processed peptides recognized by cytolytic T-lymphocytes (Ctl) on human-melanoma cells in association with Hla-A2.1 Int J Cancer 57 413 418 1:CAS:528:DyaK2cXkvVSms7g%3D 10.1002/ijc.2910570320 8169004
22. JBAG Haanen M Toebes TA Cordaro MC Wolkers AM Kruisbeek TNM Schumacher 1999 Systemic T cell expansion during localized viral infection Eur J Immunol 29 1168 1174 1:CAS:528:DyaK1MXisVGjtLc%3D 10.1002/(SICI)1521-4141(199904)29: 04<1168::AID-IMMU1168>3.0.CO;2-J 10229083
23. ABH Bakker MWJ Schreurs AJ de Boer Y Kawakami SA Rosenberg GJ Adema CG Figdor 1994 Melanocyte lineage-specific antigen Gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes J Exp Med 179 1005 1009 1:CAS:528:DyaK2cXhs1Wjtbg%3D 10.1084/jem.179.3.1005 8113668
24. V Karanikas C Lurquin D Colau N van Baren C de Smet B Lethe T Connerotte V Corbiere MA Demoitie D Lienard B Dreno T Velu T Boon PG Coulie 2003 Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus J Immunol 171 4898 4904 1:CAS:528:DC%2BD3sXot1CmsrY%3D 14568971
25. DE Speiser P Baumgaertner V Voelter E Devevre C Barbey N Rufer P Romero 2008 Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen Proc Natl Acad Sci USA 105 3849 3854 1:CAS:528:DC%2BD1cXjs1Ohsrk%3D 10.1073/pnas.0800080105 18319339
26. PG Coulie V Karanikas D Colau C Lurquin C Landry M Marchand T Dorval V Brichard T Boon 2001 A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 Proc Natl Acad Sci USA 98 10290 10295 1:CAS:528:DC%2BD3MXmvFWiur0%3D 10.1073/pnas.161260098 11517302
27. TB Stuge SP Holmes S Saharan A Tuettenberg M Roederer JS Weber PP Lee 2004 Diversity and recognition efficiency of T cell responses to cancer PLoS Med 1 149 160 1:CAS:528:DC%2BD2MXitF2qtr4%3D 10.1371/journal.pmed.0010028
28. TM Clay MC Custer MD Mckee M Parkhurst PF Robbins K Kerstann J Wunderlich SA Rosenberg MI Nishimura 1999 Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue J Immunol 162 1749 1755 1:CAS:528:DyaK1MXhtVSmurg%3D 9973438